Which of the following antipsychotics is noted for causing less weight gain?

Caplyta, also known as lumateperone, is recognized for having a more favorable side effect profile, particularly in relation to weight gain, compared to many other antipsychotics. This can be attributed to its unique mechanism of action, which targets the serotonin and dopamine systems without significantly causing weight-related metabolic changes.

In contrast, medications like Risperdal (risperidone), Seroquel (quetiapine), and Zyprexa (olanzapine) are known to be associated with significant weight gain and metabolic disturbances. This is an important consideration in treatment planning, especially for patients who may be at risk for obesity or diabetes.

The focus on metabolic side effects when prescribing antipsychotics is crucial; therefore, Caplyta is often considered a viable option for individuals who are concerned about weight gain as a side effect of their treatment. Its more balanced profile makes it a notable choice in this respect.